Xponance Inc. Buys 7,601 Shares of Kenvue Inc. (NYSE:KVUE)

Xponance Inc. raised its stake in Kenvue Inc. (NYSE:KVUE) by 2.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 277,638 shares of the company’s stock after purchasing an additional 7,601 shares during the quarter. Xponance Inc.’s holdings in Kenvue were worth $5,978,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Clearstead Advisors LLC purchased a new position in shares of Kenvue during the third quarter valued at approximately $25,000. Planned Solutions Inc. purchased a new stake in Kenvue in the fourth quarter worth $27,000. EverSource Wealth Advisors LLC purchased a new stake in Kenvue in the third quarter worth $28,000. AdvisorNet Financial Inc bought a new position in Kenvue in the third quarter worth $28,000. Finally, Global Retirement Partners LLC purchased a new position in Kenvue during the third quarter valued at $28,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

KVUE opened at $19.58 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. The firm has a 50 day moving average price of $19.84 and a 200-day moving average price of $20.16. Kenvue Inc. has a twelve month low of $17.82 and a twelve month high of $27.80.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue’s revenue was down 2.7% compared to the same quarter last year. As a group, equities research analysts predict that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 annualized dividend and a dividend yield of 4.09%.

Analysts Set New Price Targets

Several research analysts recently issued reports on KVUE shares. JPMorgan Chase & Co. decreased their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. Royal Bank of Canada dropped their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. The Goldman Sachs Group initiated coverage on shares of Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective on the stock. Sanford C. Bernstein initiated coverage on shares of Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective on the stock. Finally, William Blair initiated coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus price target of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.